TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Aggression/agitation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse oximetry reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arterial blood gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum C-terminal telopeptide of type 1 collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants with Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time 0 to The Time of the Last Observed Quantifiable Concentration (AUClast) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time 0 to Infinite Time [AUC (0-infinity)] of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Survived at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Investigator's Global Atopic Dermatitis Assessment (IGADA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer control outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: gain of VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial measurements of metabolic and inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of additional applications of short-acting local anaesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Parents Oral Health Knowledge, Attitude and Practice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Morning Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pharmacokinetics of plasma tenofovir, emtricitabine and efavirenz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-hour mycophenolate area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-hour mycophenolate Maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International RLS Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time domain analysis of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spectral analysis of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spontaneous baroreceptor sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Berg balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator-free days at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to successful discontinuation from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of cancers diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients suffering from chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Achievement of Global Renal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Base Deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Injury
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of mometasone furoate formulation 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of mometasone furoate formulation 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T2 relaxation time of medial femoral cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in T2 relaxation time of medial tibial cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in T2 relaxation time of lateral femoral cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in T2 relaxation time of lateral tibial cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 5 Point Change in AUA Symptom Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DNA re-replication indicated by the number of cells containing >4N DNA content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) Considered to be Related to Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Median Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline (Day 1) and Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median Heart Rate at Baseline (Day 1) and Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Controlled Attenuation Parameter™ (CAP™) measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in number of hospitalizations (costs)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Seated Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Response (Complete or Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Change in MA Positive Urine Drug Screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentual of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain after tonsillectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twitch mouth pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circadian rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum keratometric change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of subjects with undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cosmetic assessment of scar
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Platelet Reactivity Index (PRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Confusion Assessment Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delirium Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Internalizing and Externalizing Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Desaturation Index 4% (ODI4%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: stimulated whole salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of uterine contraction sensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of MSC infusion for steroid-resistant grade II - IV acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of MSC infusion for poor graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional Autonomy Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall CORE-OM score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sense of smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as measured by ADAScog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late loss (difference between minimal lumen diameter in stented segment immediately after and at 8 month follow up)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of a decrease of ≥ 10% in percent predicted forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: First occurrence of a decrease of ≥ 15% in percent predicted diffusing capacity of the lung for carbon monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain Perceived by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of LAMP-1 Positive Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Positive Cell for IFN Gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Proliferating Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of successful puncturing on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability of a score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intra-Operative Hemostatic Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-operative Interventions or Procedures Related to Pulmonary Artery or Pulmonary Vein Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major molecular response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incomplete complete response (iCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Success rate for arthrocentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: modified Ranking Scale (mRS) on day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Injection spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of nocturnal urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change Of sCTX Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Average Daily Pain Score (ADPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline quality of life (Stroke Specific Quality of Life Scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline motor function (Fugl Meyer Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in HE Grade at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of ultrafiltration goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop Comfort Upon Instillation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of CART22-65s in ALL subjects
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of combination CART22-65s and huCART19 in relapsed/refractory ALL subjects
Endpoint domain: Adverse events/effects
Primary endpoint: Atopic patch test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: six minutes walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: echocardiographic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Reported Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of actionable genomic abnormalities detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased lung dysfunction in HIV+ individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increased immune cell and lung cellular aging in HIV COPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of the inflammome in HIV-associated lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive functioning ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wolf motor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity functional index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Brunnstrom scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic complete response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose defined as dose limiting toxicities of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: carotid atherosclerotic plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Klotho concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects' ability to identify name and purpose of medication
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VAS scale of acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Overall Maximum Temperature of the Cornea and Surrounding Eye Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cssmax and AUCss of ethinyl estradiol (EE) and levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in total serum 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expulsion of intrauterine contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Count of Strep Mutans bacterial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With KB004 Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Adenoma/polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serious adverse device effect (SADE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Shift rate of the painless shock impedance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pacing threshold comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Platelet (PLT) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Collection Efficiency for Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 30 day survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of CMR studies with IQS > 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection
Endpoint domain: Mortality/survival
Primary endpoint: feasibility of a geriatric assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: feasibility of a weekly geriatric nursing telephone intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of FLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-Procedural Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Daily Dose of Fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing protector device (HPD) use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of a vaginal lesion due to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Record of abnormal vaginal flora (presence/absence of Nugent's score > 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Exercise-induced hypoglycemia requiring dextrose infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Detection Accuracy Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IL-1 beta concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in TNF-alpha concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Continued Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photographic Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of metabolic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Granulation and epithelial tissue progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute Change in Platelet Count From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disability assessment using Quick DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relative Value Unit (RVU) for Spine-related Interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Child BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Confidence in Navigating Vascular Access Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Confidence in Self-managing Kidney Disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Vascular Access Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider Confidence Supporting Patients Through the Vascular Access Care Process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic yield of advanced colorectal neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual and semiquantitative assessment of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes